See more : Zhi Sheng Group Holdings Limited (8370.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sinopec Shanghai Petrochemical Company Limited (SPTJF) Income Statement Analysis – Financial Results
- Arafura Rare Earths Limited (ARU.AX) Income Statement Analysis – Financial Results
- ALSO Holding AG (ALSN.SW) Income Statement Analysis – Financial Results
- Burkhalter Holding AG (BRKN.SW) Income Statement Analysis – Financial Results
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) Income Statement Analysis – Financial Results
Humanigen, Inc. (HGEN)
About Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 55.21M | 213.12M | 72.71M | 2.62M | 2.22M | 11.17M | 10.45M | 16.72M | 26.57M | 32.64M | 24.52M | 18.51M | 18.89M | 22.86M |
| General & Administrative | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Other Expenses | 0.00 | -1.61M | -1.00K | -1.00K | 324.00K | 431.00K | 125.00K | -213.00K | -154.00K | -39.00K | 113.00K | -8.00K | 915.00K | 348.00K |
| Operating Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Cost & Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 88.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.92M | 2.26M | 1.34M | 1.35M | 852.00K | 3.06M | 131.00K | 842.00K | 1.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 492.00K | -1.61M | -1.00K | -1.00K | 19.00K | 48.00K | 102.00K | 197.00K | 310.00K | 298.00K | 304.00K | 595.00K | 843.00K | 844.00K |
| EBITDA | -67.81M | -234.39M | -88.20M | -8.95M | -10.99M | -18.55M | -18.60M | -31.00M | -36.47M | -40.56M | -23.18M | -1.67M | -5.28M | -26.62M |
| EBITDA Ratio | -2,697.37% | -6,519.75% | -28,268.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,190.91% | -380.09% | -8.25% | -29.81% | -4,519.35% |
| Operating Income | -68.30M | -232.77M | -88.20M | -8.94M | -11.33M | -19.03M | -18.83M | -34.35M | -36.72M | -40.91M | -23.48M | -2.27M | -6.12M | -27.46M |
| Operating Income Ratio | -2,716.95% | -6,474.88% | -28,268.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,975.00% | -385.08% | -11.19% | -34.57% | -4,662.65% |
| Total Other Income/Expenses | -2.43M | -3.88M | -1.34M | -1.35M | -673.00K | -2.96M | -8.19M | -1.03M | -1.28M | -1.04M | -27.00K | 35.00K | 1.02M | 639.00K |
| Income Before Tax | -70.73M | -236.65M | -89.54M | -10.29M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.82M |
| Income Before Tax Ratio | -2,813.44% | -6,582.73% | -28,697.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,554.16% |
| Income Tax Expense | -492.00K | 2.26M | 1.34M | 1.35M | 179.00K | 3.49M | 256.00K | 629.00K | 1.06M | 1.05M | 140.00K | -43.00K | -108.00K | -19.00K |
| Net Income | -70.24M | -238.91M | -90.87M | -11.64M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.81M |
| Net Income Ratio | -2,793.87% | -6,645.70% | -29,125.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,550.93% |
| EPS | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| EPS Diluted | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| Weighted Avg Shares Out | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
| Weighted Avg Shares Out (Dil) | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
HUMANIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Humanigen, Inc.
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Humanigen, Inc. (HGEN) Investors of Class Action and Encourages Investors to Actively Participate
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Humanigen, Inc. (HGEN)
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
HGEN Equity Notice: ROSEN, Global Investor Counsel, Encourages Humanigen, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
HGEN INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Humanigen, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
HGEN Shareholder Update: Robbins LLP Reminds Investors of Class Action Filed Against Humanigen, Inc. (HGEN)
HUMANIGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humanigen, Inc. and Encourages Investors to Contact the Firm
Humanigen, Inc. Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Humanigen, Inc. (HGEN)
Source: https://incomestatements.info
Category: Stock Reports